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ABSTRACT 
Hemoglobin can be measured on a variety of devices using different principles of 
operation. Noninvasive pulse CO-oximetry represents the latest development in 
hemoglobin measuring technology. The technology uses principles similar to pulse 
oximetry to measure total hemoglobin, oxyhemoglobin, reduced oxyhemoglobin, 
carboxyhemoglobin and methemoglobin. Similar to the introduction of pulse oximetry to 
the medical field, pulse CO-oximetry has been met with skepticism. Since the technology 
is noninvasive and provides continuous monitoring in comparison to invasive and 
discrete techniques used in other methods, CO-oximetry purportedly provides an 
advantage in patient care. The purpose of this research is threefold: (a) to review the 
various underlying principles of measuring hemoglobin, (b) to compare the results of 
clinical studies determining the efficacy of the new pulse CO-oximeter technology, and 
(c) to provide a technical and financial basis for implementation of pulse CO-oximetry 
into a hospital or institution. These combined outcomes will determine the practicality of 
non-invasive pulse CO-oximetry in improving patient care, given the advantage of 
noninvasive, continuous monitoring. 
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1. INTRODUCTION 
Since hemoglobin concentration and oxygen saturation are indicative of a patient‟s 
ability to transport oxygen, it is routinely monitored or tested in any instance where 
oxygen transport is thought to be compromised. Additionally, hematocrit and total 
hemoglobin concentration are used perioperatively to monitor patients during procedures 
with a high risk of blood loss or hemorrhage. The measurements are used in guiding 
clinical decisions to treat low blood volume, or anemia, through medications or blood 
transfusion. 
Due to the risks associated with allogeneic blood transfusions, blood management 
strategies should attempt to stabilize a patient‟s condition by alternative means before 
resorting to transfusions. Studies have shown that a restrictive strategy of red blood cell 
transfusion is at least as effective as and possibly superior to a liberal transfusion 
strategy in critically ill patients [1]. A new noninvasive technology, pulse CO-oximetry 
monitoring, purportedly provides instantaneous hemoglobin monitoring, similar to how a 
pulse oximeter monitors oxygen saturation. Much like the implementation of pulse 
oximetry in monitoring or diagnosing hypoxemia, noninvasive pulse CO-oximetry 
requires an understanding of the methods of operation compared to the typical point of 
care or laboratory devices used to measure hemoglobin. A comparison of the 
applications, accuracy, and costs associated with the various methods of hemoglobin 
measurement will assist in defining the role of noninvasive pulse CO-oximetry in guiding 
clinical decisions.  
2. BACKGROUND 
A CO-oximeter is a device that is used to detect hypoxia, a condition in which tissue 
is deprived of oxygen. CO-oximeters measure relative blood concentrations of 
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oxygenated and reduced hemoglobin. Additionally, CO-oximeters measure the 
dysfunctional hemoglobins or dyshemoglobins; these include relative blood 
concentrations of carboxyhemoglobin and methemoglobin [2].  Total oxygen content in 
blood is dependent on two key variables: the concentration of hemoglobin, typically 
measured in grams per deciliter (g/dL), and the percentage of available hemoglobin that 
is bound with oxygen. Several devices are used to measure the concentration of 
hemoglobin, or total hemoglobin (tHb); these devices use spectrophotometry- and 
conductivity-based methods, in addition to the multi-wavelength pulse technology used 
in the recently introduced noninvasive pulse CO-oximeter.  
Some devices, such as those based on the Coulter Principle, are lab-based, provide 
discrete measurements and require the collection of arterial or venous blood samples for 
analysis. Point of Care Testing (POCT) devices are also available to measure total 
hemoglobin at the bedside using conductivity and spectrophotometric technologies. 
These devices provide only a discrete measurement and require either a capillary, 
venous or arterial blood sample. Pulse oximetry allows non-invasive continuous 
measurement of the percentage of hemoglobin in the arteries with bound oxygen.  
2.1 HEMATOCRIT 
Hemoglobin molecules in arterial blood, in normal physiologic state, are fully 
saturated with oxygen, expressed as oxygen saturation in percentage. A typical healthy 
adult has an arterial sampled oxygen saturation of 97-100%. Oxygen saturation can be 
measured noninvasively with a pulse oximeter. The oxygen carrying capacity of 
hemoglobin can be compromised by dyshemoglobins, molecules that bind with the iron 
of the hemoglobin, forming a stronger bond than oxygen.  Traditional pulse oximetry is 
not capable of measuring the common dyshemoglobins: carboxyhemoglobin (COHb) 
and methemoglobin (MetHb) and Sulfhemoglobin (SulfHb), sometimes resulting in false 
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measurements. Invasive determination of hemoglobin levels remains the most 
commonly used method to evaluate the oxygen carrying capacity of blood.  
Since hemoglobin transports oxygen from the lungs to the 
peripheral tissues, it is frequently used to indicate a patient‟s 
ability to transport oxygen. Hematocrit (HCT), the ratio of red 
blood cells (RBCs) to total blood volume is also useful in 
determining oxygen transport function. Hemoglobin accounts 
for approximately one-third of the red blood cell volume or HCT.  
To understand the relationship between the two, it is helpful to 
understand the composition of blood.  
Blood contains red blood cells (RBCs), white blood cells 
(WBCs) and platelets. These components are termed the 
„formed elements‟. HCT, sometimes referred to as packed cell volume (PCV), is a 
measurement of RBC volume, typically about 45% [3].  HCT can be measured using a 
manual method, called microhematocrit, in which a slender capillary tube of whole blood 
is spun down in a centrifuge [4]. The blood components separate as seen in Figure 1. 
The dense RBCs move to the bottom of the tube; the WBCs and platelets form a thin 
layer on top known as the buffy coat. This stacked column is known as a packed cell 
column. From the packed cell column, the volume of RBCs is compared to the total 
volume of whole blood to determine HCT; this value is typically reported as a 
percentage. Normal values, ranging from 32% to 61%, are listed in Table 1 in 
percentage as well as liters of packed cells per liter of blood (L/L) [4]. The remaining 
volume of blood, in addition to the formed elements, is clear yellow-tinted plasma.  
Figure 1: Diagram of 
packed cell column 
showing separation of 
cells and plasma after 
centrifugation.  
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Table 1  
Hematocrit Reference Ranges 
    AVERAGE RANGE 
    Percent (%) SI Units (L/L) Percent (%) SI Units (L/L) 
Adults Males 47 0.47 42–52 0.42–0.52 
Females 42 0.42 36–48 0.36–0.48 
Children  Newborn 56 0.56 51–61 0.51–0.61 
1 year 35 0.35 32–38 0.32–0.38 
6 years 38 0.38 34–42 0.34–0.42 
Data from Estridge, Barbara [4]. 
2.2 THE COULTER PRINCIPLE 
In the mid-1950s, Wallace H. 
Coulter and his brother Joseph R. 
Coulter, Jr. introduced what today is 
known as the Coulter Principle [5]. 
Their principle counts and sizes cells 
by detecting and measuring changes in 
electrical resistance as the cells pass 
through a small aperture. The 
apparatus depicted in Figure 2 has a sample tube suspended in a larger sample beaker. 
Cells are suspended in a conductive liquid which acts as an insulator. As each cell 
passes through an aperture in the smaller sample tube, it momentarily increases the 
electrical resistance of the path between the two submerged electrodes. Resulting signal 
pulses between the electrodes are amplified and counted. The number of pulses 
indicates particle count, and the size of the electrical pulse is proportional to the cell 
volume [6]. 
  
Figure 2: Functional schematic depicting the Coulter 
Principle for counting and sizing particles 
Figure from Coulter International Corp., Coulter Corporation [6]. 
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The HCT is calculated from the RBC count and the mean corpuscular volume 
(MCV), using the following equation: 
Hematocrit (%) = (RBC x MCV)/10 
2.3 HEMOGLOBIN AND COMMON DYSHEMOGLOBINS 
Hemoglobin is composed of a heme molecule and globin protein. The smallest unit 
of the heme is the pyrrole which is formed when succinyl-CoA binds with glycine. Four of 
the pyrrole molecules combine to form porphyrin or protoporphyrin IX [7]. These 
molecules combine with ferrous iron (Fe++) to form the heme molecule. Each heme 
molecule combines with a long polypeptide chain known as a globin, forming a 
hemoglobin chain. The globin is a protein of 574 amino acids in four polypeptide chains 
[3]. Each hemoglobin chain contains an atom of iron capable of binding loosely with one 
molecule of oxygen; therefore, each hemoglobin molecule containing four hemoglobin 
chains can transport four oxygen molecules. There are approximately 270,000,000 
hemoglobin molecules in each red blood cell [3]. Hemoglobin concentration is typically 
measured in grams per liter (g/L) or grams per deciliter (g/dL). Table 2 lists the 
hemoglobin reference ranges for newborns, children, adult males and adult females [4].  
Table 2  
Hemoglobin Reference Ranges 
Age/Gender Grams/Deciliter 
(g/dL) 
Grams/Liter 
(g/L) 
Newborn 16-23 160-230 
Children 10-14 100-140 
Adult males 13-17 130-170 
Adult females 12-16 120-160 
Data from Estridge, Barbara [4]. 
Carbon monoxide (CO) is a gas produced by the combustion of carbon-containing 
fuels from sources such as portable generators, oil heaters, kerosene burners, propane 
heaters, faulty furnaces, motor vehicles, stoves, gas ranges and gas heaters [8]. Once 
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inhaled, carbon monoxide can bind to hemoglobin to form carboxyhemoglobin (COHb), 
reducing the oxygen carrying capacity of the RBCs due to direct competition for the 
binding sites. The delivery of oxygen is further impaired due to allosteric effects that 
increase hemoglobin affinity for oxygen at remaining binding sites [9]. Research shows 
that COHb is normally found in less than 2.9% of the available oxygen-binding sites of 
hemoglobin. Additionally, elevated levels of carboxyhemoglobin are found in smokers 
ranging from 5 to 10% [9,10]. 
Carboxyhemoglobinemia, anemia induced by carbon monoxide poisoning (COP), 
presents clinically with varying symptoms that typically correlate with the level and 
duration of the exposure and the patient‟s prior clinical condition.  While symptoms can 
include headache, dizziness, nausea fatigue and weakness, some patients may present 
asymptomatic, making COP difficult to diagnose. COP can cause decreased myocardial 
function, respiratory alkalosis, metabolic acidosis, pulmonary edema, multiple organ 
failure and ultimately death under extreme exposure without immediate treatment [8]. 
Treatment should begin with removal of the noxious agent. The half-life of COHb 
while breathing room air is 5.3 hours; while breathing 100% oxygen at sea level the half-
life is reduced to approximately 1 hour. With 100% oxygen at 3 atmospheres, the half-life 
is further reduced to 23 minutes. Due to this reduction in half-life, hyperbaric oxygen 
therapy is the „gold standard‟ treatment in severe cases of Carboxyhemoglobinemia [11]. 
There is little correlation between clinical symptoms and COHb concentration; typically, 
a COHb concentration above 25% is considered sufficient to indicate hyperbaric oxygen 
therapy [11]. 
Methemoglobin (MetHb) is another dysfunctional form of hemoglobin incapable of 
transporting oxygen. Methemoglobinemia occurs with elevated levels of MetHb. 
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Hemoglobin contains iron in the ferrous state (Fe++) whereas MetHb contains iron in the 
ferric state (Fe+++). Similar to COHb, heme molecules in MetHb are not only incapable of 
transporting oxygen molecules, but they also have an allosteric effect, increasing the 
affinity of the remaining heme groups for oxygen. Exogenous causes of 
Methemoglobinemia include commonly prescribed drugs, herbicides, pesticides, 
chemical fumes, petrol octane boosters, and inhaled nitric oxide. Table 3 lists 
medications that have been documented to contribute to Methemoglobinemia. 
Table 3  
Medications Documented To Contribute to Methemoglobinemia 
Benzocaine Flutamide Nitroprusside Pyridium 
Celecoxib Lidocaine Nitrous oxide Riluzole 
Cetacaine Methylene blue Phenazopyridine Silver nitrate 
Chlorates Metoclopramide Phenol Sodium nitrate 
Dapsone Nitrates Prilocaine Sulfonamides  
Dimethylsulfoxide Nitric oxide Primaquine  
EMLA topical 
anesthetics 
Nitroglycerin Procaine  
Data from Barker, SJ [8].   
Methemoglobinemia can often go unnoticed or undiagnosed due to the ambiguous 
nature of the flu-like symptoms at low levels of MetHb concentrations. Patients can 
present asymptomatic at concentrations less than 15%. Concentrations greater than 
70% can lead to mortality. As with any poisoning, removal or elimination of the toxic or 
noxious agent is appropriate. Intrinsic enzyme systems will convert MetHb to 
hemoglobin at a rate of approximately 15% per hour in healthy individuals [8]. Treatment 
for elevated levels begins with maximizing the oxygen carrying capacity of normal 
hemoglobin and then facilitating the reduction of MetHb. Supplemental oxygen should be 
given followed by the administration of intravenous methylene blue for moderate to 
severe cases. Methylene blue has been shown to induce Methemoglobinemia in some 
patients if injected too rapidly. Doses greater than 15 mg/kg may induce hemolysis and 
should be avoided [9]. Some patients may present with rebound methemoglobinemia 
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after a positive response to therapy. In cases of severe methemoglobinemia, a blood 
transfusion may be necessary.  
2.4 TYPES OF ANEMIA  
Since hemoglobin concentration and oxygen saturation are indicative of a patient‟s 
ability to transport oxygen, it is routinely monitored or tested in any instance where 
oxygen transport is thought to be compromised, such as anemia. Additionally, 
hematocrit and total hemoglobin concentration are used to perioperatively monitor 
patients during procedures with a high risk of blood loss or hemorrhage. The 
measurements are used to guide clinical decisions in treating low blood volume, or 
anemia, through medications or blood transfusion. Anemia is defined by a significant 
reduction in either the number of RBCs per unit volume of whole blood, or more 
specifically too little hemoglobin in the cells [12]. Causes of anemia can be hereditary or 
extrinsic. 
Blood loss anemia occurs due to rapid blood loss or hemorrhage, resulting in 
reduced red blood cells and hemoglobin in the body. The body can replace the plasma 
of the blood in 1 to 3 days, leaving a low concentration of red blood cells. The red blood 
cell concentration can return to normal within 3 to 6 weeks [7]. 
Exposure to gamma ray radiation, excessive x-ray radiation, industrial chemicals or 
drugs can inhibit production of erythroblasts within the bone marrow, a condition termed 
bone marrow aplasia. Extreme exposure results in complete destruction of bone marrow 
and is followed in a few weeks by lethal anemia, known as aplastic anemia [7].  
Since erythroblast production in the bone marrow requires vitamin B12, folic acid, 
and intrinsic factor from the stomach mucosa, reduction of any one of these can lead to 
slow reproduction in the bone marrow. This allows the red blood cells to grow too large 
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forming megaloblasts. Megaloblastic anemia occurs because the megaloblasts are oddly 
shaped, oversized and have fragile membranes. These cells rupture easily, leaving the 
person with an inadequate number of red blood cells [7]. 
Hemolytic Anemia is caused by different abnormalities in the red blood cells, most 
hereditarily acquired. These abnormalities can cause the cells to be more fragile and 
rupture easily. The number of red blood cells formed may be normal, but the lifespan of 
the cells is often short. The cells are destroyed faster than they can be formed. In 
hereditary spherocytosis the cells are small and spherical rather than biconcave discs. 
Since they don‟t have the typical bag-like structure, the cells cannot withstand 
compression forces and rupture easily in tight vascular beds. Sickle cell anemia is 
present in 0.3-1.0 percent of West African and American blacks. The cells have an 
abnormal type of hemoglobin. This hemoglobin, when exposed to low concentrations of 
O2, precipitates into long crystals inside of the red blood cell and damages the cell 
membrane [7].  
2.5 MANAGING BLOOD LOSS ANEMIA 
Gastrointestinal, obstetric, gynecological, and various surgical procedures can all 
occur with high risk of hemorrhage, potentially leading to anemia. Anemia is also a 
common occurrence in critical care or intensive care units (ICU). There are many risks 
associated with obstetrics and gynecology. During pregnancy, clinicians should be 
prepared to use appropriate interventions to prevent or manage hemorrhage from 
conditions such as antepartum hemorrhage, an ectopic (extrauterine) pregnancy, 
miscarriage, placenta previa, placental abruption, and postpartum hemorrhage (PPH) 
[13]. During gastrointestinal procedures, blood loss can occur due to peptic ulcer 
hemorrhages, bleeding gastroesophageal varices, Mallory-Weiss tears, Dieulafoy‟s 
lesions, gastrointestinal angiomata and other conditions. Additionally, lower GI bleeding 
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can occur due to diverticular hemorrhage, angiodysplasias, anorectal hemorrhage, 
postpolypectomy site bleeding, inflammatory bowel disease and Meckel‟s diverticulum 
[14]. 
While blood transfusions are commonly used for the treatment of anemia, there is 
no universal trigger indicating blood transfusion as treatment. Current guidelines for 
critically ill and perioperative patients advise that, at hemoglobin values of under 7 g/dL, 
RBC transfusion is strongly indicated, whereas at hemoglobin values in excess of 10 
g/dL blood transfusion is unjustified. For patients with hemoglobin values in the range of 
7-10 g/dL, the transfusion trigger should be based on clinical indicators [15].  
There are divergent views on the benefits of RBC transfusions in the critical care 
setting in treating anemia. One concern is that anemia may not be well tolerated by 
critically ill patients. A study conducted between November 1994 and November 1997 
enrolled 838 critically ill patients with euvolemia, or normal blood volume, after initial 
treatment. 418 patients were administered a restrictive strategy of transfusion, in which 
red cells were transfused if the hemoglobin concentration dropped below 7.0 g/dL. The 
other 420 patients were assigned a more liberal strategy, in which transfusions were 
given when the hemoglobin concentration fell below 10.0 g/dL. Hemoglobin 
concentrations were maintained at 10.0 to 12.0 g/dL. The study found that the mortality 
rate during hospitalization was significantly lower in the restrictive-strategy group, 22.2% 
compared to 28.1% in the liberal-strategy group. It concluded that a restrictive strategy 
of red-cell transfusion is at least as effective as and possibly superior to a liberal 
transfusion strategy in critically ill patients. The exception to the study was those patients 
with acute myocardial infarction and unstable angina [16]. 
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Complications such as infections, immunosuppression, impairment of 
microcirculatory blood flow, 2,3-diphosphoglycerate deficiency, and additional 
biochemical and physiological disturbances are associated with the use of RBC 
transfusions. Levels of 2,3-diphosphoglycerate have been shown to decrease with an 
increase in storage time [17].  2,3-diphosphoglycerate affects the oxygen affinity of 
hemoglobin. Decreased levels of 2,3-diphosphoglycerate results in a decrease in the 
ability of hemoglobin to offload oxygen. Evidence also suggests that the transfusion of 
older blood, stored more than 14 days, is an independent risk factor for the development 
of multiple organ failure [17]. In a review of published literature on studies occurring 
between 1999 and 2006, Gould et al. reported that overall, critically ill patients who had 
received red blood cell transfusions had worse outcomes [17].  
A recent study by Shander et al. found that the average total cost for transfusion 
ranged from $522.45 to $1183.32 per unit of RBC transfused, with a mean of 3 to 4 units 
transfused per patient [18]. The study took into account acquisition costs, all process 
steps, and all direct and indirect overhead costs of blood transfusions in surgical patients 
at four large hospitals.  
To reduce the need for allogeneic RBC transfusions, blood cell salvage can be 
practiced. Devices such as the Cell Saver 5 (Haemonetics Corp., Braintree, MA), are 
capable of filtering blood collected in a reservoir for reinfusion [19]. A rapidly spinning 
Latham Bowl washes the concentrated red blood cells and returns a product equivalent 
to that of packed RBCs. Unprocessed salvaged blood may contain noncellular, cellular, 
or biochemical debris. The Cell Saver 5 system, if properly maintained and operated, 
eliminates 95 to 99% of unwanted contaminants [19]. Autotransfusions can also be 
provided to patients who donate their own blood before undergoing a procedure.  
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Acute normovolemic hemodilution (ANH) is an autologous blood collection 
technique that involves the removal of blood from a patient on the day of surgery, shortly 
before surgical blood loss. To maintain circulating blood volume, fluid is used to replace 
the blood as it is removed. The blood is collected in standard blood collection bags 
containing an anticoagulant agent and stored in the operating room at room 
temperature. The effect of whole blood withdrawal and replacement with crystalloid or 
colloid solution decreases arterial oxygen content, but compensatory hemodynamic 
mechanisms and the existence of surplus oxygen-delivery capacity make ANH a well-
tolerated procedure in most patients. The major factor responsible for the increased 
cardiac output observed during ANH is a decrease in viscosity as the hemoglobin level 
declines. Low blood viscosity directly decreases systemic vascular resistance and, by 
improving peripheral venous flow, increases venous return to the heart. Both 
mechanisms result in an increase in stroke volume and cardiac output [20]. 
During Acute Hypervolemic Hemodilution (AHH), a fluid is infused at the beginning 
of surgery to achieve a reduction in the hematocrit [21]. Compared to ANH, AHH has a 
higher oxygen transport capacity and peripheral oxygen delivery. It may also provide a 
greater margin of safety in older patients.  
Several physiological compensatory mechanisms also help manage blood loss; 
there is an inverse relationship between cardiac output and hemoglobin levels [22]. 
During acute hypovolemia, a condition characterized by reduced blood volume, the 
sympathetic stimulation preserves oxygen delivery to vital organs by increasing 
myocardial contractility and heart rate as well as arterial and venous vascular tone. The 
increased sympathetic tone diverts a decreasing cardiac output toward the coronary and 
cerebral circulation. Heart, lung, and cerebrovascular diseases potentially limit adaptive 
responses. Age, severity of illness, and therapeutic interventions may also affect these 
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adaptive mechanisms. Hypovolemic shock is seen when vital organ systems such as the 
kidneys, central nervous system, and heart are affected [22].  
Visual estimation is one of the most frequently used methods to determine blood 
loss, in addition to measuring hemoglobin and hematocrit. It has been demonstrated as 
inaccurate in repeated studies [23].  In a study assessing the accuracy of visual 
estimation of postpartum blood loss compared to a weight-based measurement, 
researchers at King Abdulaziz Medical City, Riyadh, Saudi Arabia found that attending 
physicians and obstetrics nurses had a tendency to underestimate blood loss by about 
30% [24]. Other studies have found evidence of overestimation [23]. Whether over or 
underestimation, gross inaccuracies have been repeatedly documented. Objective data, 
such as vital signs and hematocrit changes, are helpful in the clinical management of 
patients with large blood loss over time [23]. 
2.6 PULSE OXIMETRY 
Pulse oximetry is used to monitor for hypoxia, a condition in which the tissues are 
deprived of adequate oxygen.  Pulse oximetry is used to measure peripheral saturation 
of oxygen (SpO2) which can be used as an estimate for arterial oxygen saturation 
(SaO2). The technology is capable of distinguishing between oxyhemoglobin and 
deoxyhemoglobin. It uses two different light emitting diodes (LEDs), one emitting red 
light at approximately 660 nm and one infrared light at approximately 940 nm. Due to the 
red color, oxyhemoglobin absorbs less red light than deoxyhemoglobin. This light 
passing from the LED through the finger is measured by the photodetector positioned 
opposite to the LED. Each LED is illuminated at a particular programmed frequency. The 
software of the oximeter assumes that all of the light reaching the photodetector has the 
wavelength of the illuminated LED.  
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In order to differentiate between venous blood and arterial blood, the saturation is 
based on the difference between absorption through systole and diastole. During systole 
there is an increase in light absorption that is assumed to be created by the influx of 
arterial blood. The software determines the difference between absorption during 
diastole and systole at both wavelengths. This absorption ratio is compared to in vivo 
data to compute the SpO2 measurement.  
Pulse oximeters measure tissue light transmission at two wavelengths to estimate 
arterial hemoglobin saturation. Using only two wavelengths, these pulse oximeters 
assume the presence of only two light absorbers in the blood: oxyhemoglobin and 
reduced hemoglobin, or deoxyhemoglobin. The dyshemoglobins been shown to 
introduce error into the calculation of the oxygen saturation (SpO2) [25]. New technology 
using a multi-wavelength pulse technology is capable of differentiating between multiple 
species of hemoglobin. Masimo Corporation (Irvine, CA) has developed several devices, 
including the Rad-57 Pulse CO-oximeter and Rainbow SET technology, intended to 
measure SpO2, as well as total hemoglobin concentration (SpHb), carboxyhemoglobin 
percentage (SpCO) and methemoglobin percentage (SpMet) [25]. As with pulse 
oximeters, pulse CO-oximeters are subject to error due to skin color and motion artifact.  
3. MEASURING TOTAL HEMOGLOBIN  
Several methods are used to measure total hemoglobin content in the blood. The 
most common methods utilize spectrophotometric analysis of light absorbencies based 
on the Beer-Lambert law. Other methods take advantage of the varying conductivities of 
blood at different concentrations of RBCs.  
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3.1 SPECTROPHOTOMETRY  
Spectrophotometry is the basis for many clinical laboratory instruments, including 
those that measure hemoglobin. It is based on the fact that substances absorb or emit 
electromagnetic energy at different wavelengths. A basic spectrophotometer consists of 
a light source, wavelength selector, cuvette, and detector as seen in Figure 3. The 
detector is a radiation sensor capable of measuring the amount of power leaving the 
cuvette [26].  
 
Figure 3: Block diagram of a spectrophotometer 
Figure from Wheeler, Webster [26]. 
The cuvette holds the substance being analyzed. Substances within the cuvette 
sample absorb light selectively according to Beer‟s law. The cuvette‟s design must be so 
that it does not alter the spectral characteristics of the light as it enters or leaves the 
cuvette. The Beer‟s law relationship can be stated as follows:  
   
Where:   = radiant power arriving at the cuvette 
   = radiant power leaving the cuvette 
   = absorptivity of the sample (extinction coefficient) 
   = length of the path through the sample  
   = concentration of the absorbing substance 
The percent transmittance ( ) is a function of the radiant power arriving and leaving 
the cuvette. The absorptivity ( ) and path length ( ) are constant for an unknown. 
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Changes in  should reflect changes in the concentration of the absorbing substance. 
%T is defined as 
   
Since the relationship between concentration and %T is logarithmic, absorbance can be 
defined as: 
   
When simplified: 
   
Finally, the absorbance of a standard , of a known concentration , is determined. 
The absorbance of the unknown Au is determined by the relationship: 
 
Using the known extinction coefficients for the different forms of hemoglobin plotted in 
Figure 4, unknown concentrations of hemoglobin can be determined in whole blood 
samples. This is the basis for hemoglobin measurements is many laboratory analyzers 
and CO-oximeters.  
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Figure 4: Extinction coefficients for hemoglobin moieties 
Figure from Shapiro, Peruzzi, Templin [9] 
3.2 HEMIGLOBINCYANIDE METHOD 
The Hemiglobincyanide (HiCN) method chemically converts hemoglobin to HiCN, a 
form of hemoglobin that can be measured spectrophotometrically and has a relatively 
broad absorption maximum around a wavelength of 540 nm [27]. This technique is the 
most broadly used and appears in various technologies including: hematology analyzers, 
blood gas analyzers, stand-alone CO-oximeters and point of care testing devices.  
In general, blood samples are sent through a lyzing chamber to prepare the 
specimen for measurement. The cell membranes rupture releasing the hemoglobin. 
After the sample is diluted by a lyzing agent, a second substance, Drabkin‟s reagent, is 
added. This converts the hemoglobin to cyanmethemoglobin or HiCN [26]. Drabkin‟s 
reagent contains iron, potassium, cyanide, and sodium bicarbonate [4]. This method 
using HiCN is the accepted standard for determining hemoglobin concentration; the 
advantage is that it includes essentially all forms of hemoglobin found in the blood [26].  
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Next, the absorbance at a particular wavelength is measured and related to the 
hemoglobin concentration as determined by the spectral analysis in Figure 4. The 
hemoglobin concentration is determined from the absorbance. The absorbance of 
azidemethemoglobin, as opposed to HiCN, is sometimes used to quantify the 
hemoglobin content of the blood. An azidemethemoglobin reagent contains a lyzing 
chemical such as sodium deoxycholate, an oxidizing chemical such as sodium nitrite, 
and an azide. The oxyhemoglobin in the blood containing ferrous iron is oxidized to form 
methemoglobin, containing ferric iron. The methemoglobin then combines with the azide 
to form azidemethemoglobin. This stable compound can also be measured 
spectrophotometrically [4].  
3.2.1 HEMATOLOGY ANALYZERS 
A Complete Blood Count (CBC) is a broad screening test used to check for certain 
disorders relating to the blood. Whenever a CBC is requested from the clinical 
laboratory, samples are processed on a hematology analyzer.  A standard CBC 
includes: RBC count, WBC count, hemoglobin, HCT, Mean Corpuscular Volume (MCV), 
Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration 
(MCHC), and platelet count.  Using the Coulter Principle, the analyzer can electronically 
count and size the red blood cells. In addition to electronic particle counting, hematology 
analyzers use HiCN or azidemethemoglobin methods to spectrophotometrically measure 
total hemoglobin and the dyshemoglobin content.  
Blood samples are drawn by a phlebotomist, medical technologist or other qualified 
clinician in a collection tube containing an anticoagulant such as 
Ethylenediaminetetraacetic Acid (EDTA). The samples are labeled, bar-coded and 
processed in the laboratory. Once arriving at the hematology analyzer, the samples are 
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inserted into the analyzer and the automated measurement process is initialized by the 
lab technician.  
Patient results are recorded in a Laboratory Information System (LIS), a database 
storing any laboratory data relating to a patient. Often, data is compared to previous data 
and abnormal variations, such as a drop in hemoglobin, are flagged. If the technician 
suspects an error, measurements on the analyzer may be repeated. The particle 
counting method used by the analyzers can only count mature RBCs. If a CBC results in 
a low MCHC, it may be flagged for a manual count. A low MCHC could be caused by 
either small RBCs or IV contamination. If venous blood is drawn distal to an Intravenous 
infusion, the sample would be diluted.  
Modern analyzers have automated cleaning and Quality Control (QC) processes. 
Cleaning can take up to two hours to complete. QC is completed daily. Additional 
calibration is typically required after maintenance, as required by QC, or every 6 months 
depending on the manufacturer‟s specifications.  
3.2.2 BLOOD GAS ANALYZERS 
Blood gas analyzers are devices used for the determination of pO2, pCO2, pH, 
sodium (Na+), potassium (K+), ionized calcium (Ca++), chloride (Cl-), glucose, lactate, 
total hemoglobin (tHb) and the dyshemoglobins in arterial, venous, and capillary whole 
blood samples. Additional CO-oximetry features of some analyzers allow the 
measurement of tHb, Fraction of oxygenated Hemglobin (FO2Hb), fraction of reduced 
hemoglobin (FHHb), fraction of methemoglobin (FMetHb), and  fraction of 
carboxyhemoglobin (FCOHb) [ 28].  
The Bayer RapidLab 800 series of blood gas analyzers is a family of analyzers that 
provide different functionality. The base models can measure tHb and FO2Hb, as well as 
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the standard blood gas measurements. More featured models, such as the RapidLab 
865, have a separate CO-oximetry module that can measure the fractional components 
of the different hemoglobin derivatives. This CO-oximetry module spectrophotometrically 
measures hemoglobin. It contains an optics module and lamp, hemolyzer, and sample 
chamber. First the sample is pumped through the hemolyzer which uses ultrasonic 
sound vibrations to rupture the red blood cells and release the hemoglobin. The sample 
then enters the sample chamber for spectrophotometric measurement [28].  
The RapidLab 865 has various reagent containers, cleanser solutions, and 
calibration solutions. The calibration procedure adjusts the electronic signal from the 
photometric sensor with the concentration of the known solution. One and two-point 
calibration procedures can be performed [28].  
3.2.3 POINT OF CARE TESTING 
Several devices available for use are point of care testing (POCT) instruments 
based on HiCN or azidemethemoglobin spectrophotometric measurements. These 
devices are useful in critical care areas as well as during surgical procedures in the 
operating room. The HemoCue Hb 201+ and 201DM Analyzers, manufactured by 
HemoCue AB (Ӓngelholm, Sweden) are widely used for discrete, instant total 
hemoglobin measurements. The HemoCue uses a modified azidemethemoglobin 
reaction to spectrophotometrically measure total hemoglobin. 
The two models are similar; however, the HemoCue Hb 201DM System 
incorporates additional data management capabilities. The system consists of the 
HemoCue Hb 201 DM Analyzer, HemoCue Hb 201 Microcuvettes and the HemoCue DM 
Docking Station. The HemoCue 201 DM Analyzer spectrophotometrically measures the 
hemoglobin in the form of azidemethemoglobin as previously described. A whole blood 
21 
 
sample from the patient is required.  Capillary, venous or arterial blood can be used.  
Since capillary blood can be used, a sample can also be obtained through a minimally 
invasive finger-prick. When the microcuvette is brought into contact with the exposed 
blood, approximately 10µL is drawn into the cavity of the microcuvette through capillary 
action [29]. If a venous or arterial sample is obtained, a small amount of blood should be 
dispensed onto a hydrophobic plastic or glass slide. The sample should be well-mixed. 
The microcuvette can then be applied to the aliquot of well-mixed blood.  
The microcuvette contains sodium deoxycholate which acts initially to lyze the red 
blood cells and expose the hemoglobin. The hemoglobin is released and converted to 
methemoglobin by sodium nitrite. The methemoglobin combines with azide to generate 
azidemethemoglobin. Using an optical based method, the absorbance is measured at 
dual wavelengths: 570 nm to quantify azidemethemoglobin and 880 nm to compensate 
for sample turbidity [30]. 
The HemoCue DM Docking Station serves as a base station for charging and data 
upload. The HemoCue DM Analyzer can be customized to prompt for patient ID 
information, user ID or microcuvette lot through use of the barcode scanner. It can also 
prompt for quality control to meet regulatory requirements.  
3.3 CONDUCTIVITY-BASED METHOD 
The conductivity-based method measures the conductivity of the blood sample 
between two electrodes to determine the hematocrit. The measured conductivity is 
inversely related to the blood hematocrit.  The hemoglobin concentration is calculated by 
the assumption that hemoglobin is approximately one-third of the total hematocrit.  
Blood has a high temperature coefficient and it is essential to maintain a constant 
temperature during measurement. Conductivity-based devices have built-in thermostat-
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regulated temperature chambers to regulate the sample temperature. The most 
abundant electrolyte in plasma is sodium. Increases or decreases in sodium 
concentration will affect RBC volume and ultimately, the hematocrit measurement. 
Additionally, decreases or increases in the protein concentration of plasma can also alter 
results [31].  
3.3.1 I-STAT 
The i-STAT portable handheld is produced by Abbott Laboratories (Abbott Park, IL). 
It is capable of an array of patient-side tests including hematocrit and hemoglobin as well 
as additional tests of chemistries, electrolytes, blood gases, coagulation and cardiac 
markers. Various tests are available depending on the single-use test cartridge used.  
The i-STAT is similar to the HemoCue in that it is cartridge-based. First, whole blood 
is introduced by capillary action into the single-use micro-fabricated biosensor cartridge. 
Capillary, venous or arterial blood can be used. The conductivity is measured by the i-
STAT device and corrected for electrolyte concentration. The i-STAT provides a 
hematocrit result within 90 seconds.  
3.4 MULTI-WAVELENGTH PULSE CO-OXIMETERS 
Masimo‟s noninvasive pulse CO-oximetry technology works similar to pulse 
oximetry but uses multiple wavelengths of light to discern the dyshemoglobins. Pulse 
oximeters are not capable of measuring carboxyhemoglobin and methemoglobin; the 
presence of either of the dyshemoglobins induces error in the SpO2 measurement. The 
first device to use the pulse CO-oximetry technology was the Rad-57 handheld.  
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3.4.1 RAD-57 HANDHELD PULSE CO-OXIMETER 
The Rad-57 is a continuous noninvasive CO-oximeter, measuring arterial oxygen 
saturation of oxygenated and deoxygenated hemoglobin (SpO2), pulse rate and 
carboxyhemoglobin saturation (SpCO). The measurement is taken by placing a sensor 
on the patient, similar in appearance to the sensor used in traditional pulse oximetry 
technology, and connecting it to the device. The oxyhemoglobin, deoxyhemoglobin and 
carboxyhemoglobin species differ in their absorption of visible and infrared light. The 
sensor passes various visible and infrared light through a capillary bed, such as the 
fingertip. The photodetector receives the light and converts it to an electronic signal. The 
amount of arterial blood in tissue changes with your pulse. The varying quantities of 
arterial blood changes allow the device to determine the pulse. The device is indicated 
for use on neonate, infant, pediatric and adult patients [32]. The operating range 
accuracy for the Masimo Rad-57 is listed below in Table 4.  
Table 4  
Specifications and Operating Ranges for Masimo Rad-57 
Range 
Oxygen Saturation (%SpO2) 1-100% 
Carboxyhemoglobin Saturation (%SpCO) 1-99% 
Accuracy 
Oxygen Saturation During Motion and No Motion Conditions 
Adults, Pediatrics 70-100% ± 2 digits 
0-69% unspecified 
Neonates 70-100% ± 3 digits 
0-69% unspecified 
Carboxyhemoglobin Saturation(%SpCO) 0-40% ± 3 digits 
Resolution 
Oxygen Saturation (%SpO2) 1% 
Carboxyhemoglobin Saturation (%SpCO) 1% 
Data from Food and Drug Administration [32]. 
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4. ACCURACY OF TOTAL HEMOGLOBIN MEASUREMENTS 
To validate the use of pulse CO-oximeters to laboratory and point of care methods, 
multiple correlation studies have been completed. There is already significant variation 
between the various laboratory methods, as well as the point of care methods as 
previously discussed. Laboratory analyzers are particularly susceptible to errors due to 
sample storage and EDTA.  
4.1 CYANMETHEMOGLOBIN/AZIDEMETHEMOGLOBIN 
Gamma-Dynacare, a Canadian-based community laboratory partnership, sought to 
standardize their laboratory analyzers across their network of laboratories. A 4-way 
evaluation was developed by Bourner et al. to compare the Abbott Cell-Dyn 3500, their 
currently used analyzer, to the Beckman Coulter LH 750, Bayer Advia 120, and Sysmex 
XE2100 [33]. Using the same samples, the evaluation determined precision, within-run 
and run-to-run, linearity, and sample stability. Table 5 summarizes the coefficient of 
variation for stability and precision, as well as the average systematic error calculated 
during the linearity test. The coefficient of variation, the ratio of the standard deviation to 
arithmetic mean, is useful in comparing the reproducibility of the different variables. 
Table 5 
Laboratory Analyzer Comparison of Stability, Precision and Average Error 
 Long Term Stability 
Testing at RT - Hgb 
Long Term 
Stability Testing 
at RT - HCT 
Within Run 
Precision - Hgb 
Between Day 
Precision - 
Hgb 
Average 
Systematic 
Error 
Lab Analyzer %CV %CV %CV %CV % 
LH 750  0.80 0.77 0.4 0.7 1.9 
Advia 120 1.20 1.34 0.6 0.7 3.0 
XE 2100 0.90 0.85 0.7 0.8 2.1 
Data from Bourner, Dhaliwal and Sumner [33]. 
Within run precision for total Hemoglobin was assessed on each analyzer by 
running a quality control material a total of 10 times. The run-to-run precision or between 
day precision was intended to look at calibration drift over time; each quality control 
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material was analyzed on a daily basis. Sample stability was also measured to 
determine the effects of sample storage on the measurement. The LH750 had the lowest 
failure rate with only three occurrences outside of the total allowable error set for each 
parameter. This compares to a failure rate of 10 or more for the other analyzers. The 
LH750 was also the least affected by aged samples as shown by the stability testing with 
minimal changes in MCV and HCT. The study concluded with the selection of the LH750 
as their standard laboratory analyzer.  
Torp et al. tested the correlation between the Beckman Coulter Ac-T diff2 laboratory 
analyzer and the Nova Biomedical pHOx laboratory CO-Oximeter [34]. Using arterial 
blood samples from 33 liver transplant patients, Torp et al. found the correlation between 
the two devices to be 0.93 with a bias of 0.97 g/dL. The precision was found to be 0.5 
g/dL. The results are summarized in Table 6. 
Table 6 
Correlation of Hematology Analyzer and CO-Oximeter 
Study Hematology 
Analyzer 
CO-Oximeter Corr Bias Precision Arms 
Torp et al. 
n=471 
Coulter Ac-T diff2  
(Beckman Coulter) 
pHOx CO-Ox 
(Nova Biomedical) 
r=0.93 
 
-0.97 g/dL 
(Coulter-pHOx) 
0.58 g/dL 1.13 g/dL 
Data from Torp,K [34]. 
4.2 CONDUCTIVITY BASED METHODS 
While the conductivity-based method used by the i-STAT provides a hematocrit 
result within 90 seconds, the reliability of the measurement is debatable. A preliminary 
search on the FDA‟s Manufacturer and User Facility Device Experience (MAUDE) 
database returned several reports of discrepancies between multiple readings on the i-
STAT as well as in comparison to the lab CO-oximetry device. One report, posted 
September 24, 2007 by the manufacturer, presented a case where the measured 
hemoglobin was 7.5 g/dL and hematocrit 22%. An hour and a half later the measured 
hemoglobin was 6.8 g/dL and hematocrit of 20%. The same sample was sent to the 
26 
 
laboratory yielding a result of hemoglobin 7.9 g/dL and hematocrit of 22.5%. According 
to the report, an unnecessary transfusion was performed based on the i-STAT result of 
6.8 g/dL [35]. 
Another report, dated July 24, 2007, detailed a hematocrit measurement of 22% 
followed by another sample 10 minutes later at 25%. Since the patient didn‟t present 
with any symptoms related to low hematocrit, the samples were retested on a different 
device. The hematocrit results were 36% [35]. A study of reconstituted whole blood 
samples with varying hematocrit and hemoglobin levels compared the accuracy and 
precision of the i-STAT with the HemoCue as well as a GenS Laboratory Analyzer [36].  
Hemodilution was simulated by diluting samples with saline or lactated Ringer‟s solution. 
The HemoCue correlated well with a constant bias of 0.3 g/dL. The discrepancy of the i-
STAT increased with the solutions of lower protein content and lower hematocrit and 
hemoglobin levels. To correct for these discrepancies, the manufacturer added a 
Cardiopulmonary Bypass (CPB) mode that automatically corrects hematocrit for the 
decreased plasma protein levels typically associated with hemodilution.  
4.3 MULTIWAVELENGTH PULSE CO-OXIMETERS 
In comparing the pulse CO-oximeters to laboratory analyzers, most clinical studies 
use the Bland-Altman method for assessing agreement between two methods of clinical 
measurements [37]. To measure the agreement and determine interchangeability of two 
different methods, the Bland-Altman statistical approach compares the measured 
difference to the average of the two measurements since neither method is considered a 
“gold standard”. Similar to a t-test, the measurement correlation, bias, and precision are 
reported. 
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Allard et al. compared hemoglobin measurements from the Masimo Radical 7 to the 
Radiometer ABL820 laboratory CO-oximeter [38]. The test was composed of 20 patients 
undergoing a hemodilution protocol as approved by the internal review board. Macknet 
et al. completed a study with 49 surgical patients and 18 volunteers undergoing 
hemodilution [39]. A prototype pulse CO-oximeter from Masimo was compared to the 
Radiometer ABL 735 laboratory CO-Oximeter. Macknet et al. also reported on a single 
kidney transplantation case study where measurements of arterial samples show good 
correlation during rapidly changing concentrations of hemoglobin [40]. The precision of 
the laboratory CO-Oximeter was 0.4 g/dL compared to the 0.74 g/dL of the pulse CO-
Oximeter.  
The correlation for noninvasive pulse CO-Oximeters, as seen in Table 7, ranges 
from 0.83 to 0.88. These correlations are lower than the correlation of 0.93 seen in the 
study by Torp et al. comparing the Coulter Ac-T Diff2 laboratory analyzer and pHOx CO-
Oximeter. The studies also show that the pulse CO-Oximeter may not be as precise; 
however, the required precision for measuring hemoglobin is undetermined. The added 
value from the pulse CO-oximeters is that the continuous monitoring allows for trending, 
providing feedback for instantaneous hemoglobin changes.  
Torp et al. also presented a study on 5 patients undergoing liver transplantation [41]. 
Arterial measurements on a Nova Biomedical pHOx Plus laboratory CO-oximeter were 
compared to the Masimo pulse CO-oximeter. The study concluded that the 
measurements were comparable in accuracy and that inherent device and physiologic 
variation should also be considered.  Lamhaut et al. studied 20 patients undergoing 
urologic surgical procedures to compare the Masimo CO-Oximeter to a laboratory CO-
Oximeter [42]. This study concluded that the correlation and standard deviation are 
acceptable, but should improve with continued sensor development. Lamhaut et al. also 
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concluded that further studies to define indications and limits of the technology are 
necessary.   
Table 7 
Summary of Studies Comparing Noninvasive Pulse CO-Oximeters to Laboratory  
CO-Oximeters 
Study Sample Device 
Tested 
Standard Correlation Bias Precision Arms 
Allard A n=335 Masimo 
Radical 7 
Radiometer 
ABL 820 
r=0.84 
(p<0.001) 
-0.15 
 
0.92  
Macknet B n=1207 Prototype 
pulse CO-
Oximeter 
Radiometer 
ABL735 
r=0.827 -0.11 g/dL 1.28 g/dL 1.28 g/dL 
Macknet C, 
case study  
n=17 Prototype 
pulse CO-
Oximeter 
Radiometer 
ABL735  
 0.146g/dL 0.740 g/dL  
Torp D  n=55 Masimo 
Pulse CO-
Oximeter 
Nova 
Biomedical 
pHOx Plus 
 0.2 g/dL 0.8 g/dL 0.8 g/dL 
Lamhaut E  n=54 Masimo 
Radical 7 
Hb Lab - 
unknown 
r=0.88 0.26 g/dL 1.11 g/dL  
A Data from Allard, M [38]; B Data from Macknet, Norton, Kimball-Jones, Applegate, Martin, Allard [39]; C Data from  Macknet, 
Kimball-Jones, Applegate, Martin, Allard [40]; D Data from Torp,K [41]; E Data from Lamhaut, L [42].  
 
Since the pulse CO-oximeter has the advantage of instantaneous continuous 
monitoring, it could be proposed as a replacement for POCT devices. Jou et al. directly 
compared the Abbott Laboratories i-STAT and Masimo Pulse CO-Oximeter to the Abbott 
Diagnostics Cell-Dyn Sapphire Differential Cell Counter within a single study [43]. The 
final study was composed of 15 pediatric patients undergoing a variety of surgical cases. 
An average of 2.7 arterial blood samples were collected per patient. The Bias, precision 
and root mean square are summarized in Table 8.  
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Table 8 
Evaluation of Pulse CO-oximeter, POC, and Lab Analyzer 
Sample  Device Tested Bias Precision Arms 
n=46 i-STAT -0.26 g/dL (POC-Lab Hb) 0.46 g/dL 0.53 g/dL 
n=92 Masimo Pulse CO-
Oximeter 
0.18 g/dL (SpHb-LabHb) 1.10  g/dL 1.12 g/dL 
Data from Jou, C [43]. 
The study concluded that the directional changes provided by the continuous monitoring 
were earlier indications than the intermittent hemoglobin values provided by POCT and 
lab sampling.  
In addition to measuring total hemoglobin, Masimo‟s new noninvasive pulse CO-
Oximeter technology can measure carboxyhemoglobin and methemoglobin. The 
majority of the research surrounds the diagnosis of carbon monoxide poisoning (COP) 
and early triage of COP in the ED. Coulange et al. evaluated the reliability of pulse CO-
oximetry technology for noninvasive real-time measurement of COHb levels in victims of 
COP [11]. An investigation led by Suner et al. also concentrated on screening and 
identifying occult COP. Taking place at Rhode Island Hospital, Suner et al. put a policy 
in place requiring noninvasive SpO2 measurements being taken during the triage of all 
patients with few exceptions [10].  
According to an article submitted for publication March 9, 2006, Barker et al. 
performed a study on 20 healthy volunteers in affiliation with the University of Arizona 
College of Medicine [25]. This study aimed at evaluating the accuracy and reliability of 
Masimo‟s pulse CO-oximetry technology in measuring COHb and MetHb compared to 
lab CO-oximetry devices. As noted in the article, Touger et al. led one of the most recent 
studies of 120 emergency department (ED) patients, between January 19, 2008 and 
April 9, 2009 [39]. Dr. Michael Touger has also published research assessing the 
accuracy of using venous blood to estimate arterial COHb levels [44]. 
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The study by Coulange et al. used Masimo Rad-57 CO-oximeters to diagnose 
patients admitted to the ED suspected of COP [11]. The noninvasive measurement was 
obtained in combination with the standard work-up procedures without changing 
therapeutic strategies. A venous blood sample was obtained for analysis with an IL 682 
CO-oximeter (Instrumentation Laboratory, Barcelona, Spain) at the same time as a 
measurement using a Rad-57 CO-oximeter. The sensor of the Rad-57 was placed on 
the patient‟s middle or ring finger.  
Suner et al., working with Rhode Island Hospital, replaced all of the standard pulse 
oximeters in the public triage area as well as in the ambulances with Masimo Rad-57 
pulse CO-oximeters [10]. This allowed them to create a large sample potentially 
including any patient presenting to the ED by ambulance, personal vehicle, or walk-in. 
Nurses and technicians in the ED were trained in the use of the CO-oximeters as well as 
any factors that might affect the SpCO reading, including false nails, slender fingers, and 
inappropriate sensor positioning. Research assistants reviewed patient charts daily, 
recording SpCO as well as several other details generally recorded. This study was not 
only interested in the accuracy of the Masimo technology compared to lab CO-oximetry, 
but also the ability of the device to diagnose occult COP. Nursing staff were provided 
with questions  to ask at triage about possible environmental CO sources. These 
questions also established a smoking history, the identification on non-conventional 
heating sources, or use of equipment with combustion engines. Standard triage 
information was also recorded, such as age, gender, venous COHb, SpO2 heart rate, 
etc.  
In addition to obtaining patient data, the research assistants also interviewed 
clinicians working in the Rhode Island Hospital ED the day after any diagnosis of COP to 
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ascertain what, if any, role the SpCO measurement had in reaching the diagnosis and if 
COP was occult and detected as a result of standard SpCO triage screening.   
The study by Barker et al. was the only study to assess the accuracy of the Masimo 
Rad-57 device in diagnosing methemoglobinemia through the measurement of 
methemoglobin (MetHb); it was also the only study composed of volunteers with induced 
symptoms [25]. Twenty subjects were used for the study, 10 for COHb and 10 for 
MetHb. Each subject had peripheral venous and radial arterial cannulas inserted, 
monitoring by three-lead ECG and automated sphygmomanometer. The Masimo Rad-57 
Rainbow sensors were placed on digits 2, 3 and 4 on both hands. Blood was sampled 
periodically from the radial arterial cannula for analysis by three calibrated lab CO-
oximeters: one ABL-730 (Radiometer America, Copenhagen, Denmark) and two 
Radiometer OSM-3s (Radiometer America).  
Carboxyhemoglobinemia was induced in the first group of 10 subjects by the 
inspiration of CO at 0.3% delivered by a Drager-2A anesthesia machine. The CO was 
adjusted to 500 ppm which is designated by the US Occupational Safety and Health 
Administration as the maximum safe level for 15-minute exposure. Methemoglobinemia 
was induced in the second group of 10 subjects by the infusion of sodium nitrite, 
approved by the FDA for treatment of cyanide toxicity. The sodium nitrite was infused at 
a rate of 6mg/min for a total dose of 300 mg.  
Touger et al. assessed the agreement between the Masimo Rad-57 and the 
Siemens RapidLab 1200 blood gas analyzer [45]. Patients presenting to the Jacobi 
Medical Center suspected of COP were eligible for inclusion, with the exception of 
patients with burns involving the fingers. In a sample of 120 ED patients, clinicians were 
asked to place the finger probe on the patient‟s digit for 15 seconds, read the 
32 
 
measurement, and remove the probe. The probe was replaced on the same digit, 
allowed to recalibrate and another measurement was taken.  Arterial or venous blood 
was taken with the first measurement and sent to the laboratory for measurement of 
whole blood COHb by the Siemens RapidLab 1200.  
The first study, led by Macknet et al., investigating the ability of Masimo‟s pulse CO-
oximetry device in measuring hemoglobin concentration, included 49 patients scheduled 
for surgery and 18 healthy volunteers [39]. The subjects were monitored and a radial 
artery cannula was used for arterial blood samples. Three prototype Masimo SpCO 
sensors were used. The 18 healthy volunteers went through a hemodilution protocol, 
consisting of the withdrawal of one unit of blood and replacement with 30 ml\kg of saline, 
while the patient was monitored using the Masimo sensors. Blood samples were 
collected during each surgery or hemodilution procedure through the arterial cannula 
and analyzed by an ABL-735 CO-oximeter (Radiometer). These results were compared 
with the SpCO readings from the prototype Masimo device. The second documentation 
of this study was very similar; however, it only included 30 surgery patients and 18 
healthy volunteers [46]. The same test procedure and test devices were used.  
The results in all studies were reported using Bland and Altman methods or plots, 
used to measure agreement between two methods using bias (mean error) and 
precision (standard deviation of error) [37].The results from all studies are summarized 
in Table 9. Barker et al. showed very good agreement when measuring Methemoglobin 
with the Masimo Rad-57. The average mean difference of the pooled data was 0.00 [25]. 
Since this was the only study available measuring methemoglobin, additional research 
would need to be produced to validate this error.  
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Table 9 
Summary of Results: Linear Regression and Bland and Altman  
Study Sample  Range Correlation Bias Precision 
Carboxyhemoglobin 
Touger et al. A 
n=120 
Arterial/ 
venous 
(0-38%)  1.4% 1.96% 
Barker et al.B 
n=530 
Arterial (0-15%)  -1.22% 2.19% 
Suner et al.C 
n=64 
Venous (0-33%) r=0.72 -4.2% 4.2% 
Coulange et al.D 
n=12 
Venous (1.2 – 31.6%)  -1.5% 2.5% 
Methemoglobin 
Barker et al.B 
n=970 
Arterial (0-12%)  0.00% 0.45% 
A Data from Touger, Birnbaum, Wang, Chou, Pearson [45]; B Data from Barker, Curry, Redford, Morgan [25]; C Suner, Partridge, 
Sucov, Valente, Chee et al [10]; D Coulange, Barthelemy, Hug, Thierry, DeHaro [11]. 
 
Overall, the studies show that the device error is within that expected from the 
manufacturer specifications. The difficult part is determining what clinical values are 
acceptable. Various values were assumed for the acceptable limit of SpCO in 
diagnosing COP. Touger et al. used 15% as the cutoff for diagnosing COP [45]. Suner et 
al. left the diagnosis completely up to the clinician. In retrospect, they found that this 
cutoff was 9% for non-smokers and 13% for smokers [10]. COP is difficult to diagnose 
since symptoms are not always present. Misdiagnosis however could lead to 
unnecessary and costly hyperbaric oxygen treatment or possible other complications.  
5. FACTORS CONTRIBUTING TO MEASUREMENT UNCERTAINTY AND ERROR 
Various factors can contribute to the expanded measurement uncertainty of the total 
hemoglobin concentrations. Each method and device has unique contributors adding to 
this potential error. In POCT devices, the majority of the factors have been eliminated 
due to engineering controls; however, some sources still exist, mostly related to use 
error. Some methods also have intrinsic error which doesn‟t contribute to measurement 
uncertainty, but will potentially affect the outcome of the measurement. Since 
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noninvasive CO-oximeters are likely to compete against POCT devices, the 
measurement uncertainty is compared between those devices.  
The HemoCue is classified as a CLIA waved device by the FDA; however, use error 
has not been completely eliminated. The following can have an impact on the 
hemoglobin measurement:  
 Air bubbles within the microcuvette 
 Sampling duration 
 Improper capillary collection technique 
If a microcuvette is filled and contains air bubbles in the optical eye of the microcuvette, 
the portion through which the spectrophotometric measurement is taken in the 
HemoCue, erroneously low readings could be produced. Readings must be made within 
10 minutes of filling the microcuvette; otherwise false results may also be obtained. 
Finally, when obtaining blood samples from a finger or heel stick, the first drop of blood 
should never be used to avoid the hemolysis of blood cells mixing with any alcohol on 
the prepared skin surface. Measurement errors due to improper handling of the device 
are omitted. It is assumed that the required quality control and electronics check would 
capture any failure of the device.  
The i-STAT requires the use of an electronically-based cartridge for each sample 
measurement. Due to the nature of conductivity-based measurements, the device has 
several unique contributors to errors to error including:  
 Use of an EDTA tube 
 Decreased protein concentration in sample 
 Incorrect collection tube or technique 
 Extensive sampling duration  
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The use of an EDTA tube will cause a clinically significant error in hematocrit results. 
Venous whole blood samples collected in sodium or lithium heparin evacuated tubes is 
required. The i-STAT is primarily electronic and contains a fluid sensor to electronically 
verify the flow of fluids within the cartridges and ensure the sample is free of air 
segments. As opposed to using a “wet” quality control procedure, the i-STAT‟s electronic 
simulator can verify the conductivity circuitry used for the hematocrit test at multiple 
levels.   
As previously discussed in Section 3.3, sodium and protein concentrations can also 
affect the hematocrit measurements on the i-STAT. To address this problem, a CPB 
option was implemented for use with samples with abnormally low protein levels. The 
instrument automatically corrects hematocrit for the decreased protein levels typically 
associated with hemodilution by approximately 3% [36].  
Similar to pulse oximetry, pulse CO-oximetry is susceptible to measurement error 
from the following sources [47]:  
 Ambient light interference 
 Low peripheral perfusion 
 Motion artifact 
 Incorrect sensor positioning 
 Nail polish 
Ambient light can be absorbed by the photodetector of a pulse CO-oximeter finger probe 
and interpreted as a pulsatile absorbance signal form the patient. Shielding around the 
finger probe or photodetector helps to minimize this interference. If there is no detectable 
peripheral pulsation, the pulse CO-oximeter cannot function. Hypotension, cold 
extremities and sever vascular disease are all factors that reduce peripheral pulsations. 
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A pulse CO-oximeter cannot be used during CPB since pulsatile blood flow is typically 
not present. Patient motion can also cause error in the readings; however, advances in 
pulse oximetry and CO-oximetry technology have reduced this.  Finally, nail polish can 
also affect the measurement and should be removed before probe placement.  
6. REGULATION AND MANAGEMENT OF CO-OXIMETRY DEVICES 
Laboratory medicine is responsible for managing the Hematology analyzers, blood 
gas analyzers, and POCT devices that measure hemoglobin concentration and must 
assure their compliance with regulations. The Clinical Laboratory Improvement Act 
(CLIA) of 1988 establishes quality standards for laboratory testing based on complexity 
of test method. The Center for Medicare and Medicaid Services (CMS) administers the 
CLIA laboratory certification program in conjunction with the Food and Drug 
Administration (FDA) and the Center for Disease Control and Prevention (CDC). The 
FDA is responsible for test categorization [48]. Test methods or devices are categorized 
into three levels of complexity: waived, moderate and high. The more complicated the 
test, the more stringent the requirements. The classification of a selection of devices is 
shown in Table 10. Most of the analyzers are classified as moderately complex by the 
FDA.  
Laboratories can apply for various certificates for accreditation. A Certificate of 
Waiver permits a laboratory to perform only waved tests. Waved tests have been 
determined to be so simple and accurate that there is little risk of error if the test is 
performed incorrectly. CLIA waved instruments are designed to be used by individuals 
not trained in laboratory science.  A Certificate of Compliance is issued to laboratories to 
perform moderate or high complexity testing. For laboratories conducting moderate or 
high complexity testing, CMS conducts surveys to determine a laboratory‟s regulatory 
compliance. Additionally, by law, these labs must also participate in proficiency testing 
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three times per year to evaluate whether the laboratory‟s results are accurate and 
consistent with peer laboratories. Biennial inspections are completed by an accreditation 
program approved by CMS; this allows the laboratory to apply a Certificate of 
Accreditation [48]. 
Table 10 
CLIA Test Complexity for a Selection of tHb Instruments  
Manufacturer Model Classification 
Hematology/Chemistry Analyzers 
Beckman-Coulter  LH-750 Moderate 
Siemens Advia 1200 Moderate 
Sysmex XE-2100 Moderate 
CO-Oximeter 
Instrumentation Laboratory IL682 Moderate 
Nova CO-Oximeter Moderate 
Blood Gas Analyzer 
Radiometer ABL90 Moderate 
Siemens Rapidlab1200 Moderate 
Point of Care Testing 
Abbott Laboratories i-STAT Waved/Moderate* 
A-VOX Systems AVOXimeter 4000 Moderate 
HemoCue HB 201 System Waved 
*i-Stat classification dependent on specific cartridge analytes  
Data from CLIA Test Complexity Database [49]. 
 
The HemoCue has been classified as a waved test by the FDA. Engineering controls 
are built in that require completion of appropriate quality control before the device can be 
unlocked for use. Quality control requires several control standards of varying 
hemoglobin levels. Multiple levels of quality control are carried out throughout the day as 
indicated by the manufacturer, licensure organizations, and good lab practices. Patient 
information may be entered; information on the microcuvette or cartridge is also entered 
to ensure the disposables have not expired.  In addition to CMS accreditation, The 
College of American Pathologists (CAP) also oversees laboratory medicine. These 
agencies review the POCT programs during inspection to ensure the users are trained, 
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proper procedures for quality control are being followed, and the devices are being 
maintained in accordance with the manufacturer‟s recommendations.  
Hematology analyzers and blood gas analyzers are all classified as moderately 
complex due to the staff knowledge and training required, use of reagents, complicated 
operational steps and calibration and quality control procedures. The instruments 
measure several other analytes in addition to hematocrit and hemoglobin.  
Noninvasive pulse CO-oximeters are classified as monitoring devices by the FDA 
and subsequently do not fall under the CAP and CMS accreditation of laboratory 
medicine. Like pulse oximeters, these devices use either a disposable or reusable finger 
probe. The reusable or “reposable” finger probes are guaranteed for approximately 500 
uses. Preventative maintenance is carried out annually using a simulator to verify 
performance. Routine quality control is not necessary. The device can be operated by a 
respiratory therapist, registered nurse, certified nursing assistant, or doctor.  
7. DISCUSSION 
The previously discussed studies provided a comparison of total hemoglobin 
measurements between various hematology analyzers, POCT devices, and noninvasive 
pulse CO-oximeters. Significant variation was found by Bourner et al. when comparing 
multiple hematology analyzers. The average error of these instruments when compared 
to the lab‟s existing analyzer ranged from 1.9% to 3.0%. Even at the low end of the 
reference range, 7 g/dL, an error of 3% on a total hemoglobin concentration would be 
0.21 g/dL. This is minimal error considering if a value in the range of 7 g/dL was 
obtained, the measurement would likely be retested.  
Correlation studies comparing pulse CO-oximeters to laboratory analyzers found the 
correlation of the pulse oximeters to range from 0.83 to 0.88. When comparing blood gas 
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analyzers to laboratory analyzers, correlations as high as 0.93 were found. Pulse CO-
oximeters do not correlate as well to laboratory analyzers as do blood gas analyzers or 
other table top CO-oximetry devices.   
Other studies looked at the precision of the pulse CO-oximeter compared to 
laboratory analyzers. The precision found ranged from 0.74 to 1.28 g/dL between 
several studies. One study in particular compared the precision of an i-STAT and pulse 
CO-oximeter to a laboratory analyzer. The precision of the i-STAT and Pulse CO-
oximeter was found to be 0.46 g/dL and 1.10 g/dL. Assuming the confidence interval is 
65% for a normal distribution, the precision could be too low for obtaining a confident 
measurement of total hemoglobin. If the actual value of hemoglobin was 7 g/dL, the 
measured value could lie between 5.9 and 8.10 g/dL. If 7 g/dL was being used as a 
restrictive transfusion indicator, the patient may be unnecessarily transfused at a 
hemoglobin concentration of 5.9 g/dL when using a SpHb monitor.  
As previously indicated, pulse CO-oximeters are most likely to replace POCT 
devices since hematology and blood gas analyzers are still going to be required for 
measuring other analytes. POCT devices are subject to much more use error than pulse 
CO-oximeters due to the sample collection that is necessary for measurement. 
Specimens or tubes may be mislabeled causing a turn-back and another sample 
collection from the patient. The wrong tube may be used for the wrong method. An 
incorrect sample type could be obtained, i.e. venous as opposed to arterial, leading to 
invalid results that may not be discovered.  If a questionable measurement is obtained, 
the typical protocol is to run QC on the POCT device to validate the performance and 
then rerun the test. Significant opportunity for human error or use error is still inherent in 
the POCT devices.  
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Since the pulse CO-oximeter is classified as a monitoring device, it is much less 
regulated than the POCT devices. POCT devices require extensive maintenance, QC 
and training which must be maintained constantly to meet the requirements of licensure 
organizations. CLIA waved devices still require extensive management of the device by 
laboratory medicine.  
Finally, the costs associated with POCT are likely significantly higher. Cartridges for 
the hemoglobin test on the i-STAT can cost hundreds of dollars. The microcuvettes used 
with the HemoCue are much less expensive, but require closer monitoring to maintain 
storage requirements and guarantee expired lots of microcuvettes are not used. 
Additional savings in reduced transfusion costs can also be argued.  
One of the limitations of this research is the lack of detailed research. A number of 
the studies cited in this paper are summaries published through conferences. An 
additional limitation to the studies is the difficulty of testing the instrument at 
physiological extreme levels of hemoglobin concentration. Volunteer testing using 
hemodilution methods cannot explore the upper limitations of the hemoglobin 
concentrations. In the studies using surgical patients, extensive variability between 
subjects may exist. There are many controls to consider such as blood sample for 
azidemethemoglobin and conductivity-based measurements or minimizing motion 
artifact with SpHb probes.  
Another limitation to the analysis of error and uncertainty of SpHb monitoring 
compared to POCT is that POCT instruments are not calibrated using control samples. 
While measurement uncertainty in the device exists, the control samples and test 
cartridges are only used for QC which does not actually alter the methods of 
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measurement. Expanded measurement uncertainty from a calibration process cannot be 
derived.  
8. CONCLUSION 
To summarize the research discussed, noninvasive pulse CO-oximetry provides a 
clear advantage of measuring carboxyhemoglobin and methemoglobin as well as 
continuous monitoring compared to current POCT and laboratory analyzers. While Torp 
et al. concluded that hemoglobin measurements were comparable in accuracy, it was 
suggested that inherent device and physiologic variation should also be considered. It 
has been shown that arterial and venous blood samples are not rheologically 
comparable; hematocrit is higher in venous blood than in arterial blood [50]. Additionally, 
variation can be introduced depending on how the patient is positioned. Education of 
clinicians will be necessary to better understand how the values obtained from pulse 
CO-oximeters relate to the health and diagnosis of the patient.  
While noninvasive pulse CO-oximetry already provides an improvement to patient 
care through the noninvasive and trending capabilities, the technology also provides 
potential cost savings to the hospital and a reduced effort in maintenance and regulation 
of the devices in comparison to current POCT devices. Considering the proven reduction 
in transfusion frequency when using SpHb-guided blood and the total costs per unit of 
blood ranging between $522 and $1,183, significant savings could be realized. This 
reduction in blood transfusions would also reduce the risks to the patients. It could be 
assumed that the noninvasive nature of the instrument would induce less stress on the 
patient since blood samples would not be necessary.  As the market for SpHb 
monitoring continues to grow, it will continue to be the responsibility of each hospital to 
perform correlation studies as is already the case with new devices in laboratory 
medicine.   
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APPENDIX I: ACRONYMS 
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AAH Acute Hypervolemic Hemodilution 
ANH Acute Normovolemic Hemodilution 
CAP College of American Pathologists 
CBC Complete Blood Count 
CDC Center for Disease Control and Prevention 
CLIA Clinical Laboratory Improvement Act 
CMS Center for Medicare and Medicaid Services 
CO Carbon Monoxide 
COHb Carboxyhemoglobin 
COP Carbon Monoxide Poisoning 
CPB Cardiopulmonary Bypass 
ED Emergency Department 
EDTA Ethylenediaminetetraacetic Acid 
FDA Food and Drug Administration 
HCT Hematocrit 
Hgb/Hb Hemoglobin 
ICU Intensive Care Unit 
MAUDE Manufacturer and User Facility Device Experience 
MCH Mean Corpuscular Hemoglobin 
MCHC Mean Corpuscular Hemoglobin Concentration 
MCV Mean Corpuscular Volume 
MetHb Methemoglobin 
PCV Packed Cell Volume 
POCT Point of Care Testing 
PPH Postpartum Hemorrhage 
RBC Red Blood Cell 
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SpCO Carboxyhemoglobin Saturation 
SpO2 Oxygen Saturation 
SulfHb Sulfhemoglobin 
tHb Total hemoglobin 
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